Tissue therapies posts small loss
By Renate Krelle
Thursday, 10 February, 2005
Thursday, 10 February, 2005
Tissue Therapies Limited (ASX:TIS) has released its half-year results, recording a net loss of $445,400, in line with budget expectations.
At December 31, the company had cash reserves of almost $4 million, bolstered by a $1.5 million capital raising in October last year.
It spent $524,000 on research and development, and banked revenue of $152,5000 from research grants and interest.
Related News
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
